9th Annual BMRP Investigator Meeting - Abstract

Metabolomics in Inflammatory Bowel Disease: A Novel Diagnostic Test

Jesse S. Siffledeen1, Levinus Dieleman1, Carolyn M. Slupsky2 and Richard N. Fedorak1,a

1
Division of Gastroenterology, University of Alberta (Alberta, Edmonton, Canada); 2Department of Nutrition, University of California, Davis (Davis, California, U.S.A.)

Metabolomics is the study of small molecule metabolites in biological systems. Metabolomic profiles have potential to differentiate patients with IBD from those without IBD. Patients with Crohn’s disease (CD) (N=77) completed a Harvey Bradshaw Index (HBI) and patients with ulcerative colitis (UC) (N=42) a Modified Mayo score for disease activity. Patients with IBS served as matched controls (N=120). Each patient provided a spot urine sample and metabolite concentrations and profiles were derived by analysis of 600 MHz Nuclear Magnetic Resonance (NMR) spectra.  We observed clear differences in urinary metabolite profiles between individuals with IBD and controls (78% sensitivity and 89% specificity). Furthermore, within the IBD group, we were able to distinguish CD metabolomic profiles from those of UC. UC and CD disease activity was reflected in the metabolite profiles. This study illustrates that urinary metabolomics is effective at distinguishing IBD patients from normal subjects, and can also distinguish patients with CD from patients with UC. This methodology represents a highly novel potential diagnostic tool for IBD that has enormous potential to provide insight into IBD pathogenesis.

a Principal Investigator

 

Last updated 05/10/2011